Effective population study of Qinghuang powder in the treatment of myelodysplastic syndrome

Study on the mechanism of mitochondrial mediated methylation of MDS nuclear genome and HIF-1 a expression regulation of Qinghuang Powder

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064066

Enrollment

Unknown

Registered

2022-09-25

Start date

2022-09-25

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic syndrome

Interventions

Qinghuang Powder Group:Qinghuang Powder Group 1 capsule

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for myelodysplastic syndrome; age 18 to 75 years old; no recent chemotherapy plan; no serious heart, liver and kidney complications; not participating in other clinical studies; voluntary testing, and signed informed consent.

Exclusion criteria

Exclusion criteria: Patients with serious side effects while taking the drug; patients with known allergies to the drug; pregnant or breastfeeding women; patients on a chemotherapy plan; psychiatric patients.

Design outcomes

Primary

Measure	Time frame
Routine blood test;HIF-1a signaling pathway related genes and effectors;	—

Countries

China

Contacts

Public ContactTang Xudong

tangxudong001@163.com13520016513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026